CMF-OS low grade, but high aggressive.
CMF-OS is an extremely rare type of malignant tumor, and shares the same biological behavior as osteosarcoma, so it is defined a subtype of osteosarcoma and follows the same principles of treatment [2]. After medical history collection and physical examination, regional lesion was initially evaluated by CT and MRI,distal metastasis was excluded by Pet/CT. Besides, bone metabolism, e.g., alkaline phosphatase (ALP), Lactic Dehydrogenase (LDH), should also be tested to evaluate bone metabolism [5].
For low-grade osteosarcoma, it is well established that extensive resection should be firstly considered, followed by sensitive chemotherapy or radiotherapy if there was residual tumor tissue. Although first line chemotherapy for osteosarcoma are cisplatin and doxorubicin with or not with high dose of methotrexate, obviously, the regular chemotherapy plan is not fit for the low proliferative osteosarcoma as CMF-OS, and the poor results of chemotherapy for this patient confirmed the idea. Methotrexate plays an anti-tumor effect mainly by inhibiting the DNA synthesis of tumor cells [6]. While the vincristine targets at microtubules, which mainly inhibit the polymerization of tubulin, affect the formation of spindle microtubules, and finally stop mitosis in the metaphase [7]. The reasons for choosing MTX and vincristine are experimental treatment, considering their relatively low toxicity. However, after two courses of chemotherapy, the neurological status deteriorated very quickly, and palliative decompression had to be carried out emergently to preserve neural function.
According to NCCN guideline, radiotherapy should be considered for patients with positive margins of resection, partial resection or unresectable cases [8]. For this patient, he received large fractionation radiotherapy of total 60 Gy. Until he passed away (6 months after operation), no local or distant recurrence was found.
Proactive treatments are suggested for azygos vein with tumor thrombosis
Azygos vein is usually located at the right anterior side of spine (from T1 to L2), it connects with right subcostal vein, inferior vena cava, ascending lumbar vein, accessory hemiazygos vein and intercostal veins. During en bloc spondylectomy, attention should be paid to this venous system [9]. For this case, medical images showed venous thrombosis in azygos vein. Without intervention, the patient died from heart failure caused by thrombus in atrium which probably came from azygos. Therefore, resection of azygos with thrombosis should be actively considered in case of migrating to atrium. As far as we know, this was the first report about heart failure caused by azygos tumor thrombus.
The dilemma of benefits and loses
To the beginning, tumor tissue should be resected as much as possible, including vertebrae, paravertebral tumor tissue, and azygos vein with tumor thrombosis. Two stages were needed to finish the operation. Firstly, azygos vein with thrombosis should be resected, and tumor tissue in the anterior and lateral side should be freed through anterior approach. Secondly, 3D-Printed prosthesis vertebrae or titanium mesh can be used to achieve spine reconstruction through posterior approach. However, tumor tissues were so extensive that it was hard to complete en bloc resection. The possibility of complete resection was pretty low, and the complication rate was very high, even made his life in danger. Therefore, en bloc resection was impossible, and intralesional resection was chosen to preserve neurological function.
Besides, tumor thrombosis was found in azygos vein, which was also a rare phenomenon and difficult to treat. The question was whether should we have an excision of azygos vein with thrombosis at great risk. Even though it is a major operation [3], the resection of azygos vein with thrombosis may save his/her life. Because thrombus formed in azygos vein may migrate upward, and finally result in superior vena cava and heart thrombosis [10]. However, reconsider the tumor can only be partially resected, and both the patient and surgeons did not want to take the risk of resection of an azygos vein with thrombosis. Furthermore, poor prognosis was deduced considering the unresectable tumor and poor responsive to neoadjuvant chemotherapy. Based on the above issues, palliative resection of tumors by posterior approach was chosen with the main purpose of saving nerval function. Then chemotherapy plan was readjusted according to postoperative pathology results, similarly, whether to remove the anterior vertebral body depended on postoperative pathology report and the results of multidisciplinary consultation.
The balance of benefit and lose was hard to achieve when we just considered the state of illness, let alone the very poor financial compensation he could get. However, it is common to see families suffer extreme poverty because of serious diseases in many countries. Furthermore, life expectancy is not always easy to judge according to tumorous classification and stage. All in all, it is difficult to balance possible complications,benefits and the financial burden after operation.
Finally, this patient received palliative decompressive surgery. Unfortunately, he died of heart failure caused by thrombus from azygos vein, which was not anticipated. In other words, resection of azygos vein with thrombosis in time may save his life. This was a bitter lesson, worthy of our attention.